Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

NCT02348008 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Clear Cell Renal Carcinoma

Interventions

DRUG: MK-3475
DRUG: Bevacizumab
DRUG: MK-3475
DRUG: Bevacizumab

Sponsor

Arkadiusz Z. Dudek, MD

Collaborators

[object Object]
[object Object]